title: Physostigmine treatment of progressive supranuclear palsy.
abstract: Cognitive and extrapyramidal effects of cholinomimetic therapy were evaluated in 8 patients with progressive supranuclear palsy. Each was randomized to a 10-day double-blind crossover trial of physostigmine and placebo. Physostigmine treatment was associated with marginal and inconsistent changes in long-term memory, suggesting that cholinergic therapy alone is insufficient to restore cognitive function. Motor scores remained unchanged.
authors: Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
authors: I
authors: I
authors: Litvan
authors: C
authors: C
authors: Gomez
authors: J R
authors: JR
authors: Atack
authors: M
authors: M
authors: Gillespie
authors: A M
authors: AM
authors: Kask
authors: M M
authors: MM
authors: Mouradian
authors: T N
authors: TN
authors: Chase
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy / Q000209:etiology*; D008875:Middle Aged; D010830:Physostigmine / Q000627:therapeutic use*; D013494:Supranuclear Palsy, Progressive / Q000150:complications / Q000188:drug therapy*
chemical_list: D010830:Physostigmine